{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.15","upperLimit":"49.71","value":"44.4"},{"groupId":"OG001","lowerLimit":"19.89","upperLimit":"29.01","value":"24.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"description":"Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \\>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population includes only participants concurrently enrolled in Stage 2 and only those who had been randomized at the time of approval of Protocol WO30070 v6. The measurable disease populations were defined as participants in the respective ITT populations with at least one measurable lesion according to RECIST v1.1 based on investigator assessment.","reportingStatus":"POSTED","timeFrame":"Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)","title":"Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}